Big Pharma goes under the hammer

Indian generics company Sun Pharma has dropped $16.36 billion (US$11.75 billion) in cash to acquire Organon, offering shareholders more than double what their shares were worth earlier this month in a bid to muscle its way into the upper ranks of the pharma industry.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here